The purposes of this study are to assess rapidly innovative treatment methods in patients
with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS
and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish
and maintain the required infrastructure to perform multiple therapeutic trials that may
involve investigational drugs, approved agents not currently used for treatment of ARDS, or
treatments currently used but whose efficacy has not been well documented.
National Institute on Deafness and Other Communication Disorders (NIDCD)
Phase 3
2004-12-01
This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected
into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing
loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours).
This trial aims to compare the efficacy of oral prednisone vs. methylprednisolone injected
into the middle ear for the treatment of moderate-to-severe, sudden sensorineural hearing
loss (inner ear hearing loss affecting one ear that occurs over less than 72 hours).
Allogeneic Transplantation From Related Haploidentical Donors
Completed
Stanford University
Phase 2
2000-08-01
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+
selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative
regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
